EVH:NYE-Evolent Health Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 10.07

Change

+0.39 (+4.03)%

Market Cap

N/A

Volume

2.01M

Analyst Target

USD 11.67
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.28 (+0.37%)

USD 13.78B
DOCS Doximity Inc

+1.23 (+2.17%)

USD 10.98B
WEAV Weave Communications Inc

-0.10 (-0.89%)

USD 0.83B
AMWL American Well Corp

-0.02 (-0.28%)

USD 0.12B
CTEV Claritev Corporation

-0.21 (-1.01%)

N/A
PHR Phreesia Inc

+0.66 (+2.59%)

N/A
TDOC Teladoc Inc

+0.03 (+0.39%)

N/A
VEEV Veeva Systems Inc Class A

-1.36 (-0.60%)

N/A
FOXO FOXO Technologies Inc.

+0.01 (+4.35%)

N/A

ETFs Containing EVH

ACTV LeaderShares® Activist L.. 0.00 % 0.00 %

+0.27 (+0.89%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.49% 44% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.49% 44% F 17% F
Trailing 12 Months  
Capital Gain -66.58% 11% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.58% 11% F 2% F
Trailing 5 Years  
Capital Gain 109.79% 100% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 109.79% 100% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 28.30% 90% A- 88% B+
Dividend Return 28.30% 90% A- 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 69.76% 30% F 12% F
Risk Adjusted Return 40.57% 80% B- 55% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.